In addition, technical issues related to the evaluation of Ki67 proliferative index and the future perspectives of the application of Ki67 immunostaining in endocrine and neuroendocrine neoplasms is discussed. This evidence concerns the gene MKI67 and neuroendocrine neoplasm.